CN104689217A - Traditional Chinese medicine composition for treating stomach cancer - Google Patents
Traditional Chinese medicine composition for treating stomach cancer Download PDFInfo
- Publication number
- CN104689217A CN104689217A CN201510142239.7A CN201510142239A CN104689217A CN 104689217 A CN104689217 A CN 104689217A CN 201510142239 A CN201510142239 A CN 201510142239A CN 104689217 A CN104689217 A CN 104689217A
- Authority
- CN
- China
- Prior art keywords
- medicine composition
- chinese medicine
- rhizoma
- gastric cancer
- rhizoma atractylodis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 206010017758 gastric cancer Diseases 0.000 title claims abstract description 28
- 208000005718 Stomach Neoplasms Diseases 0.000 title claims abstract description 27
- 201000011549 stomach cancer Diseases 0.000 title claims abstract description 27
- 238000011282 treatment Methods 0.000 claims description 27
- 241001250596 Pleione Species 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 14
- 239000003826 tablet Substances 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 238000013270 controlled release Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 241000628997 Flos Species 0.000 claims description 2
- 239000007910 chewable tablet Substances 0.000 claims description 2
- 229940068682 chewable tablet Drugs 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 210000000214 mouth Anatomy 0.000 claims description 2
- 229940023488 pill Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 20
- 238000002474 experimental method Methods 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 4
- 230000012010 growth Effects 0.000 abstract description 2
- 241000271309 Aquilaria crassna Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 241000092665 Atractylodes macrocephala Species 0.000 abstract 1
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 240000001659 Oldenlandia diffusa Species 0.000 abstract 1
- 241001522129 Pinellia Species 0.000 abstract 1
- 241001250598 Pleione bulbocodioides Species 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 description 19
- 206010062717 Increased upper airway secretion Diseases 0.000 description 10
- 208000026435 phlegm Diseases 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- 206010047700 Vomiting Diseases 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 206010000077 Abdominal mass Diseases 0.000 description 3
- 206010017553 Furuncle Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 201000011591 microinvasive gastric cancer Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
- 229960001674 tegafur Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000018779 Globus Sensation Diseases 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- -1 absorption carrier Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 208000010540 rapid respiration Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 208000009146 rhinoscleroma Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicines, and discloses a traditional Chinese medicine composition for treating stomach cancer. The traditional Chinese medicine composition comprises spreading hedyotis herb, atractylodes macrocephala koidz, Chinese atractylodes, pleione bulbocodioides, fructus amomi, tangerine peel, pinellia ternate, flose caryophylli, agarwood, rhizoma cyperi and radix glycyrrhizae. Pharmacology experiments show that the traditional Chinese medicine composition combines multiple medicinal materials, has a remarkable inhibiting effect on the growth of a tumor, and is high in total effective rate.
Description
Technical field
The invention belongs to technical field of Chinese medicines, relate to a kind of Chinese medicine composition, be specifically related to a kind of Chinese medicine composition for the treatment of gastric cancer.
Background technology
The mortality rate of gastric cancer has accounted for first of alimentary tract cancer mortality rate, and gastric cancer seriously endangers the life and health of people.1/4th are accounted for because of cancer mortality in because of the crowd of disease death.Early gastric cancer is through operative treatment, and 5 years survival rates of patient can reach 90%, and prognosis bona.The general non-evident sympton of early gastric caacer in right actual life, only a few peoples have the digestive symptoms of Nausea and vomiting or similar Peptic Ulcers, and therefore early gastric cancer is difficult to find.And gastric cancer middle and advanced stage patient, health is relatively weak, and body organ function declines, lassitude, immunity degradation, the ability of immunocyte opposing stomach cancer cell infringement, cause stomach cancer cell diffuse faster, patient pain deepens, easily there is the transfer case of gastric cancer middle and advanced stage, the situations such as hepatic metastases appears in cancerous cell, Bone tumour, make state of an illness high progression.
The method mainly excision of current western medical treatment cancer, this method is by the cutting tissue of affected area, and this method is high relative to conservative treatment cure rate, and comparatively large to patient body injury, danger is higher.Adopt the method for radiotherapy or chemotherapy to kill the method for cancerous cell also more conventional, but also part normal cell can be killed while killing cancerous cell, this method side effect is large, and medical expense is high, and cure rate is low.
Due to the above-mentioned shortcoming of doctor trained in Western medicine, chemical medicine, treatment by Chinese herbs gastric cancer comes into one's own in recent years gradually.
Summary of the invention
For solving the deficiency of chemical medicine, the invention provides a kind of Chinese medicine composition for the treatment of gastric cancer.
For realizing object of the present invention, the present invention is according to Zu Fanghe clinical application experience for many years, and the Chinese medicine composition of the treatment gastric cancer provided is prepared by following Chinese crude drug:
Herba Hedyotidis Diffusae, the Rhizoma Atractylodis Macrocephalae, Rhizoma Atractylodis, Pseudobulbus Cremastrae Seu Pleiones, Fructus Amomi, Pericarpium Citri Reticulatae, the Rhizoma Pinelliae, Flos Caryophylli, Lignum Aquilariae Resinatum, Rhizoma Cyperi and Radix Glycyrrhizae.
Through the clinical experiment that inventor is long-term, when finding that the Chinese medicine composition that the present invention treats gastric cancer is prepared from by the raw material of following weight portion, effect is better.
Herba Hedyotidis Diffusae 60-180, Rhizoma Atractylodis Macrocephalae 30-90, Rhizoma Atractylodis 30-90, Pseudobulbus Cremastrae Seu Pleiones 60-180, Fructus Amomi 10-60, Pericarpium Citri Reticulatae 60-180, Rhizoma Pinelliae 60-180, Lignum Aquilariae Resinatum 30-90, Rhizoma Cyperi 120-180 and Radix Glycyrrhizae 30-90.
The present invention treats the Chinese medicine composition of gastric cancer, preferably, is made up of the raw material of following weight portion:
Herba Hedyotidis Diffusae 140, the Rhizoma Atractylodis Macrocephalae 40, Rhizoma Atractylodis 40, Pseudobulbus Cremastrae Seu Pleiones 160, Fructus Amomi 20, Pericarpium Citri Reticulatae 100, the Rhizoma Pinelliae 80, Lignum Aquilariae Resinatum 90, Rhizoma Cyperi 140 and Radix Glycyrrhizae 60.
In Chinese medicine composition of the present invention, the pharmacological action of each component is as follows:
Herba Hedyotidis Diffusae:
Sweet, light, cool.Gui Jing, enters stomach, large intestine, small intestine meridian.Heat-clearing and toxic substances removing, inducing diuresis to remove edema, promoting blood circulation and stopping pain.For acute appendicitis (appendicitis), furuncle toxic swelling, jaundice due to damp-heat, the diseases such as dysuria; Furuncle carbuncle is controlled in external, venom.
The Rhizoma Atractylodis Macrocephalae:
Bitter, sweet, temperature.Return spleen, stomach warp.Invigorating the spleen and benefiting QI, dampness diuretic, hidroschesis, antiabortive.For insufficiency of the spleen lack of appetite, abdominal distention is had loose bowels, phlegm retention vertigo and palpitation, edema, spontaneous perspiration, frequent fetal movement.Rhizoma Atractylodis Macrocephalae spleen invigorating, stomach function regulating, antiabortive.For insufficiency of the spleen lack of appetite, loose stool of having loose bowels, frequent fetal movement.
Rhizoma Atractylodis:
Pungent, bitter, temperature.Return spleen, stomach, Liver Channel.Drying damp and strengthening spleen, expelling wind and cold, improving eyesight.For distension and fullness in the abdomen, have loose bowels, edema, beriberi flaccidity of feet with lamenness, rheumatic arthralgia, anemofrigid cold, nyctalopia.
Pseudobulbus Cremastrae Seu Pleiones:
Sweet, micro-pungent, cool.Return liver, spleen channel.Heat-clearing and toxic substances removing, dissipating phlegm and resolving masses.For carbuncle furunculosis, scrofula sucutaneous nodule, tuberculous lymphadenitis, snake bite and insect sting.
Fructus Amomi:
Pungent, temperature.Return spleen, stomach, kidney channel.Removing dampness is whetted the appetite, warming spleen and stopping diarrha, regulates the flow of vital energy antiabortive.For turbid damp obstructing in middle-JIAO, gastral cavity painful abdominal mass is not hungry, Deficiency and coldness of spleen and stomach, and vomiting is had loose bowels, pregnancy reactions, frequent fetal movement.
Pericarpium Citri Reticulatae:
Bitter, pungent, temperature.Return lung, spleen channel.Regulating qi-flowing for strengthening spleen, drying dampness to eliminate phlegm.For fullness in the epigastrium and chest, lack of appetite and vomiting, cough with copious phlegm.
The Rhizoma Pinelliae:
Pungent, temperature; Poisonous.Return spleen, stomach, lung meridian.Drying dampness to eliminate phlegm, stopping nausea and vomiting by lowering the adverse flow of QI, dissolving lump and resolving mass.For abundant expectoration cough with asthma, phlegm retention vertigo and palpitation, dizziness due to wind-phlegm, syncope due to accumulation of phlegm is had a headache, vomiting regurgitation, and breast gastral cavity painful abdominal mass is vexed, globus hystericus; Raw with external treatment carbuncle sucutaneous nodule.Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) is used for stopping nausea and vomiting by lowering the adverse flow of QI.
Lignum Aquilariae Resinatum:
Pungent, bitter, tepor.Return spleen, stomach, kidney channel.Promoting the circulation of QI to relieve pain, warming middle-JIAO to arrest vomiting, helping inspiration to relieve asthma.For the vexed pain of breast abdominal distention, gastrofrigid vomiting singultus, QI rising in reverse order of suffering from a deficiency of the kidney dyspnea with rapid respiration.
Rhizoma Cyperi:
Pungent, micro-hardship, micro-sweet, flat.Return liver, spleen, tri-jiao channel.Promoting QI circulation for relieving depression, menstruction regulating and pain relieving.For stagnation of QI due to depression of the liver, breast, the side of body, abdominal distention, dyspepsia, breast gastral cavity painful abdominal mass is vexed, and colic of cold type is suffered from abdominal pain, distending pain of the breast, menoxenia, amenorrhea dysmenorrhea.
Radix Glycyrrhizae:
Sweet, flat.GUIXIN, lung, spleen, stomach warp.Invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.For weakness of the spleen and stomach, fatigue and weakness, shortness of breath and palpitation, cough with copious phlegm, the anxious pain of gastral cavity abdomen, extremity contraction, carbuncle sore tumefacting virus, cushion toxicity, strong.
Pharmaceutically acceptable carrier can also be added in Chinese medicine composition of the present invention, be applied in mode that is oral or parenteral the patient needing this treatment.For time oral, conventional solid preparation can be made into, as tablet, capsule, soft capsule, dispersible tablet, oral liquid, granule, chewable tablet, oral cavity disintegration tablet, drop pill, slow releasing tablet, slow releasing capsule, controlled release tablet, controlled release capsule, make liquid preparation if water or oil-suspending agent or other liquid preparation are as syrup etc.
Chinese medicine composition of the present invention can adopt the conventional method in existing pharmaceutical field to produce, and can add various pharmaceutically acceptable carrier when needs.Described carrier comprises the excipient, filler, binding agent, wetting agent, disintegrating agent, absorption enhancer, surfactant, absorption carrier, lubricant etc. of pharmaceutical field routine.
Chinese medicine composition of the present invention is when making oral formulations, and selectable filler has: starch, Icing Sugar, calcium phosphate, calcium sulfate two water thing, dextrin, microcrystalline Cellulose, lactose, pregelatinized Starch, mannitol etc.; Selectable binding agent has: sodium carboxymethyl cellulose, PVP-K30, hydroxypropyl cellulose, starch slurry, methylcellulose, ethyl cellulose, hypromellose, gelling starch etc.; Selectable disintegrating agent has: dried starch, polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose etc.; Selectable lubricant has; Magnesium stearate, Pulvis Talci, sodium lauryl sulphate, micropowder silica gel etc.
The present invention compared with prior art has the following advantages:
1. pharmacological experiment confirms, the present invention's all taste medical materials 5 use, have significant inhibitory action to the growth of tumor, total effective rate is high.
2. clinical experiment confirms, Chinese medicine composition of the present invention can extend 5 year life cycle of patient, improves the life quality of patient.
3. the full side of the present invention is only made up of 10 taste materials, and flavour of a drug are simplified, and raw medicinal material is common medicine, without in great shortage.
4. drug synergism of the present invention is strong, and dosage is few, and expected toxic and side effects is low.
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, the present invention is not limited only to following examples.Within the scope of the invention or not departing from content of the present invention, spirit and scope, the change carried out the present invention, combination or replacement, be apparent for a person skilled in the art, and be included within the scope of the present invention.
Embodiment 1
The preparation of capsule of the present invention.
Take Herba Hedyotidis Diffusae 140g, Rhizoma Atractylodis Macrocephalae 40g, Rhizoma Atractylodis 40g, Pseudobulbus Cremastrae Seu Pleiones 160g, Fructus Amomi 20g, Pericarpium Citri Reticulatae 100g, Rhizoma Pinelliae 80g, Lignum Aquilariae Resinatum 90g, Rhizoma Cyperi 140g and Radix Glycyrrhizae 60g, dry, mix homogeneously, pulverizes, and crosses 80 mesh sieves, sterilizing, direct fill capsule.
Embodiment 2
The preparation of capsule of the present invention.
Take Herba Hedyotidis Diffusae 180g, Rhizoma Atractylodis Macrocephalae 60g, Rhizoma Atractylodis 90g, Pseudobulbus Cremastrae Seu Pleiones 160g, Fructus Amomi 20g, Pericarpium Citri Reticulatae 100g, Rhizoma Pinelliae 80g, Lignum Aquilariae Resinatum 60g, Rhizoma Cyperi 100g and Radix Glycyrrhizae 60g, dry, mix homogeneously, pulverizes, and crosses 80 mesh sieves, sterilizing, direct fill capsule.
Embodiment 3
The preparation of capsule of the present invention.
Take Herba Hedyotidis Diffusae 100g, Rhizoma Atractylodis Macrocephalae 90g, Rhizoma Atractylodis 60g, Pseudobulbus Cremastrae Seu Pleiones 100g, Fructus Amomi 10g, Pericarpium Citri Reticulatae 80g, Rhizoma Pinelliae 100g, Lignum Aquilariae Resinatum 60g, Rhizoma Cyperi 180g and Radix Glycyrrhizae 90g, dry, mix homogeneously, pulverizes, and crosses 80 mesh sieves, sterilizing, direct fill capsule.
Embodiment 4
The preparation of granule of the present invention.
Take Herba Hedyotidis Diffusae 140g, Rhizoma Atractylodis Macrocephalae 40g, Rhizoma Atractylodis 40g, Pseudobulbus Cremastrae Seu Pleiones 160g, Fructus Amomi 20g, Pericarpium Citri Reticulatae 100g, Rhizoma Pinelliae 80g, Lignum Aquilariae Resinatum 90g, Rhizoma Cyperi 140g and Radix Glycyrrhizae 60g, dry, mix homogeneously, pulverize, cross 80 mesh sieves, add starch, sucrose, use 70% appropriate amount of ethanol, granulate, dry, sterilizing, pack, every bag of 10g.
Embodiment 5
The preparation of granule of the present invention.
Take Herba Hedyotidis Diffusae 60g, Rhizoma Atractylodis Macrocephalae 3g, Rhizoma Atractylodis 30g, Pseudobulbus Cremastrae Seu Pleiones 90g, Fructus Amomi 20g, Pericarpium Citri Reticulatae 80g, Rhizoma Pinelliae 80g, Lignum Aquilariae Resinatum 60g, Rhizoma Cyperi 120g and Radix Glycyrrhizae 90g, dry, mix homogeneously, pulverize, cross 80 mesh sieves, add starch, sucrose, use 70% appropriate amount of ethanol, granulate, dry, sterilizing, pack, every bag of 10g.
Embodiment 6
The preparation of Tablets.
Take Herba Hedyotidis Diffusae 140g, Rhizoma Atractylodis Macrocephalae 40g, Rhizoma Atractylodis 40g, Pseudobulbus Cremastrae Seu Pleiones 160g, Fructus Amomi 20g, Pericarpium Citri Reticulatae 100g, Rhizoma Pinelliae 80g, Lignum Aquilariae Resinatum 90g, Rhizoma Cyperi 140g and Radix Glycyrrhizae 60g, dry, mix homogeneously, pulverize, cross 80 mesh sieves, add starch, microcrystalline Cellulose, use 70% appropriate amount of ethanol, granulate, tabletted.
Experiment of Zoology
Chinese medicine composition of the present invention affects Transplantable Murine gastric cancer subcutaneous transplantation tumor
1 material
1.1 medicines: Chinese medicine composition of the present invention (parts by weight: Herba Hedyotidis Diffusae 140, the Rhizoma Atractylodis Macrocephalae 40, Rhizoma Atractylodis 40, Pseudobulbus Cremastrae Seu Pleiones 160, Fructus Amomi 20, Pericarpium Citri Reticulatae 100, the Rhizoma Pinelliae 80, Lignum Aquilariae Resinatum 90, Rhizoma Cyperi 140 and Radix Glycyrrhizae 60); Ftorafur.
1.2 animals: SPF level KM mice 60,4 week age, male and female half and half, body weight 23 ± 5 grams, divides into groups according to completely random group technology;
1.3 tumor strains: stomach cancer cell MGC-803 tumor strain.
2 experimental techniques
2.1 modelings: stomach cancer cell MGC-803 cell culture in RPMI-1640,37 DEG C, 5%CO
2, pH value 7.2 ~ 7.4, lower cellar culture, on average within every two days, go down to posterity once, being prepared into density to normal saline during exponential phase is 3.0 × 10
7individual/ml single cell suspension, aseptically be injected in mouse peritoneal, inoculate latter 7 days and see the obvious enlargement of mouse peritoneal, now, de-neck is put to death, and puts into the beaker filling 75% ethanol and soaks 2-3 minute, and the mice after sterilization is put into superclean bench, expose abdominal part, put into aseptic reagent bottle by asepsis injector extraction ascites for subsequent use.Above-mentioned ascites trypan blue is counted, with normal saline dilution, adjustment cell number to 1.0 × 10
7individual/ml, is inoculated in the right oxter of mice, every 0.4ml.After 2 weeks, select oxter, right side to have the mice 48 that diameter is 5mm-7mm scleroma, be divided into 4 groups at random, often organize each 12.
2.2 grouping and administrations:
Mice dosage and mode:
Every day timed drug administrations once, administration volume 0.1ml/10g, successive administration 10 days, group medication and dosage as follows:
Model group: the normal saline of gavage equivalent;
Matched group: ftorafur, 10mg/kg;
Low dose group of the present invention: 100mg/kg;
High dose group of the present invention: 200mg/kg;
Weigh, pluck tumor, weigh, calculate tumour inhibiting rate, computing formula is as follows:
3. statistical method
Data acquisition SPSS17.0 software carries out statistical analysis, measurement data with
represent, before and after treatment, Indexes Comparison adopts t inspection; Enumeration data adopts X2 inspection.P < 0.05 represents that difference has statistical significance.
4. experimental result
The impact of table 1 Chinese medicine composition of the present invention and tumour inhibiting rate heavy on Mouse Stomach carcinoma
Remarks:
*represent and compare P < 0.05 with model group;
#represent and compare with matched group: P < 0.05
Administration is after 10 days, and matched group has 10 mouse survivals, and model group has 8 mouse survivals, and high low dose group mice of the present invention is without death.Visible Chinese medicine composition of the present invention can reduce the mortality rate of cancer mice.
Experimental result is pointed out: matched group, high low dose group of the present invention all obviously can suppress the growth of Mouse Gastric Cancer glucagonoma, but Chinese medicine composition high low dose group tumor killing effect of the present invention is more outstanding, have significant difference compared with matched group, visible Chinese medicine composition of the present invention is being better than existing Western medicine to Gastric Cancer MGC-803 solid tumor inhibitory action.
Partial clinical experimental data
1. case selection and experiment grouping
Selection is diagnosed as patients with gastric cancer 100 example, wherein the oldest person 65 years old, reckling 35 years old, 50.8 years old mean age; Be divided into two groups at random: treatment group 50 example, matched group 50 example.Two groups of state of an illness, age, sex etc., through statistical procedures P > 0.05, there was no significant difference.
2. Therapeutic Method
Treatment group: give capsule prepared by the embodiment of the present invention 1, every day 3 times, each 6,30 days courses for the treatment of.Take 2 courses for the treatment of continuously.
Matched group: give for lucky capsule for treating difficult to understand.
3. efficacy determination
(1) effective: tumor tumor body reduces more than 10%, and subjective symptoms is obviously improved, cardinal symptom disappears;
(2) effective: tumor tumor body reduces 3 ~ 10%, and clinical symptoms is obviously improved;
(3) improve: tumor tumor body reduces 1 ~ 3%, clinical symptoms is improved;
(4) invalid: tumor tumor body continues to increase, and clinical symptoms is without improvement or increase the weight of.
4, therapeutic outcome
4.1 liang of group treatment comparitive study, see table 2.
Table 2 liang group treatment comparitive study
Table 2 result shows, and treatment group obvious effective rate is higher, and tumor killing effect is more outstanding, is significantly better than matched group.Treatment group total effective rate 96.0% is also apparently higher than matched group 82.0%.Visible Chinese medicine composition of the present invention, compared with existing western medicine, has better therapeutic effect.
After 4.2 liang of group treatments, patient compares, see table 3 life cycle.
A table 3 liang group compares life cycle
| Group | Case load (people) | 0.5 year | 1 year | 2 years | 3 years | 4 years | 5 years |
| Treatment group | 50 | 50 | 48 | 42 | 32 | 28 | 18 |
| Matched group | 50 | 49 | 45 | 39 | 30 | 22 | 11 |
Table 3 result shows, treatment group patient 5 years survival rates are about 36%, and far above 22% of matched group, visible Chinese medicine composition of the present invention can improve 5 years survival rates of patient to a great extent, compared with existing Western medicine, achieves unexpected technique effect.
Claims (6)
1. treat a Chinese medicine composition for gastric cancer, it is characterized in that, prepare by containing, for example lower Chinese crude drug: Herba Hedyotidis Diffusae, the Rhizoma Atractylodis Macrocephalae, Rhizoma Atractylodis, Pseudobulbus Cremastrae Seu Pleiones, Fructus Amomi, Pericarpium Citri Reticulatae, the Rhizoma Pinelliae, Flos Caryophylli, Lignum Aquilariae Resinatum, Rhizoma Cyperi and Radix Glycyrrhizae.
2. the Chinese medicine composition for the treatment of gastric cancer according to claim 1, is characterized in that, when being prepared from by the raw material containing, for example lower weight portion, effect is better:
Herba Hedyotidis Diffusae 60-180, Rhizoma Atractylodis Macrocephalae 30-90, Rhizoma Atractylodis 30-90, Pseudobulbus Cremastrae Seu Pleiones 60-180, Fructus Amomi 10-60, Pericarpium Citri Reticulatae 60-180, Rhizoma Pinelliae 60-180, Lignum Aquilariae Resinatum 30-90, Rhizoma Cyperi 120-180 and Radix Glycyrrhizae 30-90.
3. the Chinese medicine composition for the treatment of gastric cancer according to claim 2, is characterized in that, best results when being prepared from by the raw material containing, for example lower weight portion:
Herba Hedyotidis Diffusae 140, the Rhizoma Atractylodis Macrocephalae 40, Rhizoma Atractylodis 40, Pseudobulbus Cremastrae Seu Pleiones 160, Fructus Amomi 20, Pericarpium Citri Reticulatae 100, the Rhizoma Pinelliae 80, Lignum Aquilariae Resinatum 90, Rhizoma Cyperi 140 and Radix Glycyrrhizae 60.
4. the Chinese medicine composition of the treatment gastric cancer according to claim 1-3, can also add pharmaceutically acceptable carrier.
5. the Chinese medicine composition of the treatment gastric cancer according to claim 1-4, is characterized in that it is oral formulations.
6. the Chinese medicine composition of the treatment gastric cancer according to claim 1-5, is characterized in that described oral formulations is tablet, capsule, soft capsule, dispersible tablet, oral liquid, granule, chewable tablet, oral cavity disintegration tablet, drop pill, slow releasing tablet, slow releasing capsule, controlled release tablet, controlled release capsule, syrup, decoction etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510142239.7A CN104689217B (en) | 2015-03-28 | 2015-03-28 | A kind of Chinese medicine composition for the treatment of gastric cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510142239.7A CN104689217B (en) | 2015-03-28 | 2015-03-28 | A kind of Chinese medicine composition for the treatment of gastric cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104689217A true CN104689217A (en) | 2015-06-10 |
| CN104689217B CN104689217B (en) | 2016-04-06 |
Family
ID=53337041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510142239.7A Expired - Fee Related CN104689217B (en) | 2015-03-28 | 2015-03-28 | A kind of Chinese medicine composition for the treatment of gastric cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104689217B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101612383A (en) * | 2009-07-21 | 2009-12-30 | 吕启贵 | A kind of medicine for the treatment of gastric cancer, esophageal carcinoma and preparation method thereof |
| CN104189763A (en) * | 2014-09-15 | 2014-12-10 | 陈海林 | Traditional Chinese medicine composition for treating stomach cancer |
-
2015
- 2015-03-28 CN CN201510142239.7A patent/CN104689217B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101612383A (en) * | 2009-07-21 | 2009-12-30 | 吕启贵 | A kind of medicine for the treatment of gastric cancer, esophageal carcinoma and preparation method thereof |
| CN104189763A (en) * | 2014-09-15 | 2014-12-10 | 陈海林 | Traditional Chinese medicine composition for treating stomach cancer |
Non-Patent Citations (2)
| Title |
|---|
| 唐武军: "郁仁存老师治疗胃癌经验总结", 《中国实验方剂学杂志》 * |
| 郝迎旭等: "胃癌的中西医结合治疗", 《河南肿瘤学杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104689217B (en) | 2016-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104208540B (en) | Compound traditional Chinese medicine for treating gastric cancer and preparation method thereof | |
| CN104784624A (en) | Traditional Chinese medicine for treating dyspepsia | |
| CN102106965B (en) | Composition for treating acute injury of soft tissue and application thereof | |
| CN102671178A (en) | Chinese medicinal composition for treating nephrotic syndrome and uremia and preparation method and application thereof | |
| CN104147388B (en) | Traditional Chinese medicine composition for treating migraine and preparation method thereof | |
| CN105535495A (en) | Chinese medicinal composition for treating esophageal cancer by reinforcing vital essence and strengthening primordial qi and preparation method | |
| CN104689217B (en) | A kind of Chinese medicine composition for the treatment of gastric cancer | |
| CN103446387B (en) | Traditional Chinese medicine composition for treating hyperthyroidism and preparation method thereof | |
| CN103040975B (en) | Traditional Chinese medicine composition for nursing and treating infantile diarrhea | |
| CN101810667A (en) | Medicine composition for auxiliary treatment of cancer | |
| CN100431584C (en) | Chinese medicinal formulation for caring and enlarging breast | |
| CN105521332A (en) | Traditional Chinese medicinal composition for treating anal fissure, and preparation method and application thereof | |
| CN105213758A (en) | A kind of Chinese medicine composition for the treatment of chronic pneumonia and preparation method thereof | |
| CN104622994A (en) | Pharmaceutical composition for treating chronic gastritis | |
| CN104258037A (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method thereof | |
| CN105168628A (en) | Medicine for treating cellulitis and preparation method thereof | |
| CN104707035B (en) | A kind of Chinese medicine composition for the treatment of combined spinal-epidural anesthesia Headache | |
| CN101028352A (en) | Chinese-medicinal preparation for treating ischiodynia | |
| CN1857533A (en) | Chinese medicine preparation for preventing and treating cerebral thrombus and its sequel | |
| CN105288171A (en) | Pharmaceutical composition for treating male climacteric syndrome | |
| CN104800724B (en) | Improve the medicine of toxicity after chemotherapy of tumors | |
| CN104784608B (en) | Improve the preparation method of the medicine of toxicity after chemotherapy of tumors | |
| CN105497818A (en) | Traditional Chinese medicine preparation for treating rheumatic heart disease | |
| CN105287798A (en) | Lipid-lowering and slimming recovery pill | |
| CN103948900B (en) | A kind of preparation method for the treatment of atrophic gastritis Tibetan medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Hao Xinjie Inventor after: Wang He Inventor after: Fan Xiaoping Inventor after: Wang Xiaobin Inventor before: The inventor has waived the right to be mentioned |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160229 Address after: 266000 Shandong province Qingdao City, Fushun Road No. 9 Applicant after: Hao Xinjie Applicant after: Wang He Applicant after: Fan Xiaoping Applicant after: Wang Xiaobin Address before: The 277719 Shandong province Linyi Lanling County Township Xue Village No. 431 Applicant before: Wang Lei |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160406 Termination date: 20170328 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |